Showing 5041-5050 of 5646 results for "".
- Nature Gene Therapy Publishes Preclinical Data of Ocugen’s OCU400 Genetic Modifier to Treat Retinitis Pigmentosahttps://modernod.com/news/nature-gene-therapy-publishes-preclinical-data-of-ocugens-ocu400-genetic-modifier-to-treat-retinitis-pigmentosa/2477345/Ocugen announced the publication in Nature Gene Therapy of preclinical data of nuclear hormone receptor gene NR2E3 as a genetic modifier and therapeutic agent to treat multiple retinal degenerative diseases. OCU400 (NR2E3-AAV) has received two orphan drug designatio
- Prism Vision Group Announces Agreement With the Retina Group of Washingtonhttps://modernod.com/news/prism-vision-group-announces-agreement-with-the-retina-group-of-washington/2477344/Integrated eyecare services organization PRISM Vision Group announced an agreement to add The Retina Group of Washington (RGW), which provides retinal and macular care in Washington D.C., Virginia and Maryland. Terms of the deal were not disclosed. “Medicine is changing around us an
- Registration Open for Eyecelerator, a New Conference Aimed at Accelerating Eye Care Advancementshttps://modernod.com/news/registration-open-for-eyecelerator-a-new-conference-accelerating-eye-care-advancements/2477339/Registration is now open for Eyecelerator, a new business conference aimed at furthering ophthalmic innovation. The conference is a joint venture between the American Academy of Ophthalmology (AAO) and the American Society of Cataract and Refractive Surgery (ASCRS). The inaugural Eyecelerator con
- EyePoint Pharmaceuticals Announces Positive Topline 36-Month Follow-up Data for Second Phase 3 Study of Yutiqhttps://modernod.com/news/eyepoint-pharmaceuticals-announces-positive-topline-36-month-follow-up-data-for-second-phase-3-study-of-yutiq/2477336/EyePoint Pharmaceuticals announced positive topline 36-month follow-up data from the second phase 3 trial of Yutiq (fluocinolone acetonide intravitreal implant) 0.18 mg 3-year micro-insert for the treatment of chronic noninfectious uveitis affecting the posterior segment of the eye. “The d
- Eyevance Pharmaceuticals launches Tobradex ST in the United Stateshttps://modernod.com/news/eyevance-pharmaceuticals-launches-tobradex-st-in-the-united-states/2477333/Eyevance Pharmaceuticals has announced the US launch of Tobradex ST (tobramycin/dexamethasone ophthalmic suspension) 0.3%/0.05% following the company’s acquisition of the product in late 2019. Tobradex ST is an FDA approved, fixed-dose topical antibiotic and corticosteroid combination indicated f
- Zeiss Concludes Acquisition of Saxonia Systems and Creates Carl Zeiss Digital Innovation in Dresden, Germanyhttps://modernod.com/news/zeiss-concludes-acquisition-of-saxonia-systems-and-creates-carl-zeiss-digital-innovation-in-dresden-germany/2477335/Zeiss has concluded its acquisition of Saxonia Systems AG, a specialist for customized software solutions. The fully acquired company will now operate as Carl Zeiss Digital Innovation. The new unit will support the Zeiss segments with their digital projects and play a leading role in terms of inn
- VEO Ophthalmics to Support The Masket Foundation to Raise Awareness of Aniridiahttps://modernod.com/news/veo-ophthalmics-to-support-the-masket-foundation-to-raise-awareness-of-aniridia/2477331/VEO Ophthalmics announced that, in honor of Rare Disease Day, it is collaborating with the Masket Foundation to raise awareness of aniridia and treatment options for aniridia. Aniridia is a serious ophthalmic rare disease in which a patient’s iris does not develop properly. VEO Ophthalmics is the
- Penn Medicine Study Finds Missing One Eye Appointment Can Lead to Vision Loss in Elderlyhttps://modernod.com/news/penn-medicine-study-finds-missing-one-eye-appointment-can-lead-to-vision-loss-in-elderly/2477319/A Penn Medicine study discovered that missing one ophthalmology appointment within a 2-year period could cause dec
- Companies in US Drug Supply Chain Unveil Pilot Project to Track Counterfeit Medicineshttps://modernod.com/news/companies-in-us-drug-supply-chain-unveil-pilot-project-to-track-counterfeit-medicines/2477315/Several companies, including Pfizer, GlaxoSmithKline, Roche, Eli Lilly, Novartis, Sanofi, Novo Nordisk, Amgen and Gilead Sciences, have created a blockchain-based platform to track prescription products across the supply chain in an effort to better stem the flow of counterfeit medicines, a
- Eyevance Pharmaceuticals Appoints Julie Speed as Chief Commercial Officerhttps://modernod.com/news/eyevance-pharmaceuticals-appoints-julie-speed-as-chief-commercial-officer/2477316/Eyevance Pharmaceuticals has appointed Julie Speed to the position of Chief Commercial Officer. In her new role, Ms. Speed will be responsible for developing the commercial strategy and overseeing the growth of Eyevance’s product portfolio, including Flarex (fluorometholone acetate) 0.1%, Freshk